AV Lopinavir

Aus coViki
Wechseln zu: Navigation, Suche
  • GET 2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients. Extract
  • GET 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 Extract
  • GET 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use Extract
  • GET 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression Extract
  • GET ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan Extract
  • GET 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR Extract
  • GET 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR Extract
  • GET 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR Extract
  • GET ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19 Extract
  • GET ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply Extract
  • GET 2020. Lopinavir-ritonavir in severe COVID-19 Extract
  • GET 2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer Extract
  • GET 2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? Extract
  • GET 2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. Extract
  • GET 2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Extract
  • GET 2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? Extract
  • GET 2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19). Extract
  • GET 2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium. Extract
  • GET 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China. Extract
  • GET 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients. Extract
  • GET 2020. Does lopinavir measure up in the treatment of COVID-19? Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19. Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19. Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19. Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19. Extract
  • GET 2020. A Trial of Lopinavir-Ritonavir in Covid-19. Extract
  • GET 2020. Lopinavir pharmacokinetics in COVID-19 patients. Extract
GET 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19. Extract
  • GET 2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Extract
  • GET 2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Extract
  • GET 2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. Extract
  • GET 2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective. Extract
  • GET 2020. Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma. Extract
  • GET 2020. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. Extract
  • GET 2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir. Extract
  • GET 2020. Does lopinavir really inhibit SARS-CoV-2? Extract
  • GET 2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement. Extract
  • GET 2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge